Dr Lal PathLabs Limited announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, during a board meeting held on April 30, 2026. The company reported a consolidated revenue from operations of INR 7,027 Million for the current quarter, representing a growth of 6.50% compared to the preceding quarter’s revenue of INR 6,598 Million and a 16.61% increase from INR 6,026 Million in the corresponding quarter of the previous year. Consolidated profit for the period stood at INR 1,322 Million, showing a significant increase of 44.64% over the previous quarter’s INR 914 Million, though it saw a decline of 14.98% compared to INR 1,555 Million in the same quarter last year. The board also recommended a final dividend of INR 4 per equity share for the financial year 2025-26.

Dr Lal PathLabs is one of India’s oldest and largest medical diagnostics chains, providing a wide range of laboratory services across India and Asia. The company operates a network of laboratories and collection centers, offering thousands of diagnostic tests ranging from routine screenings to specialized investigations. In recent strategic moves during 2025 and early 2026, the company approved the acquisition of a 100% stake in Shahbazkers Diagnostic Centre Private Limited to strengthen its presence in Mumbai and announced plans to incorporate a wholly-owned subsidiary in Dubai, UAE, to expand its international footprint. Additionally, the company re-appointed (Hony) Brig. Dr. Arvind Lal as Executive Chairman for another five-year term starting in 2027.